SCHEMBL15528301

SCHEMBL15528301

CC1O[C@H](C)Cn2ncc([N+](=O)[O-])c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 1/20 0.41
LRRK2 Q5S007 2/20 0.38
POLB P06746 2/20 0.36
NPC1 O15118 1/20 0.36
HTT P42858 2/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
GAA P10253 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HPGD P15428 1/20 0.33
CNR1 P21554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26644039 0.79 LRRK2 (0.38) ALDH1A1RAB9AMAPTLRRK2POLB
SCHEMBL15528227 0.69 LRRK2 (0.37) ALDH1A1LRRK2POLBKDM4EGAA
SCHEMBL31569009 0.68 MAPT (0.36) ALDH1A1MAPTPOLBLMNASMN1; SMN2
SCHEMBL22421100 0.68 ALDH1A1 (0.34) ALDH1A1RAB9AMAPTMEN1KMT2A
SCHEMBL8795481 0.65 ALDH1A1 (0.35) ALDH1A1MAPTPOLBLMNACYP1A2
SCHEMBL21553240 0.64 MEN1 (0.38) ALDH1A1POLBKDM4ETDP1GAA
SCHEMBL16469649 0.64 VCAM1 (0.36) ALDH1A1MAPTPOLBHTTLMNA
SCHEMBL28434366 0.64 MEN1 (0.40) POLBKDM4ETDP1GAACYP1A2
SCHEMBL15625103 0.64 ALDH1A1 (0.36) ALDH1A1RAB9AMAPTPOLBKDM4E
SCHEMBL15625049 0.64 PIM1 (0.43) ALDH1A1POLBKDM4EGAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2844658-B1 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE GENENTECH INC (US) 2019-03-20 EP disclosed
US-9212186-B2 Bicyclic pyrazole LRRK2 small molecule inhibitors GENENTECH, INC. (US) 2015-12-15 US disclosed
EP-2844658-A1 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE F. Hoffmann-La Roche AG (CH) 2015-03-11 EP disclosed
US-20150051201-A1 BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS GENENTECH, INC. (US) 2015-02-19 US disclosed
WO-2013164323-A1 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051201-A1 BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS LRRK2, PARK7, PINK1 ALDH1A1 2479/4885RAB9A 128/4885MAPT 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.